| Literature DB >> 32814780 |
Maryam Moazzam-Jazi1, Leila Najd Hassan Bonab1, Asiyeh Sadat Zahedi1, Maryam S Daneshpour2.
Abstract
Type 2 diabetes (T2D) is emerging as one of the serious public health issues in both developed and developing counties. Here, we surveyed the worldwide population differentiation in T2D-associated variants and assessed the genetic burden of the disease in an ongoing Tehran Cardio-Metabolic Genetic Study (TCGS) cohort represented the Iranian population. We found multiple SNPs that were significantly depleted or enriched in at least one of the five populations of 1,000 Genome Project (African, American, East Asian, European, and South Asian) as well as the Iranian population. Interestingly, TCF7L2, a well-known associated gene with T2D, harbors the highest number of enriched risk alleles almost in all populations except for East Asian, where this gene embraces the largest number of significantly depleted risk alleles. The polygenic risk score (PRS) of the enriched risk alleles was calculated for 1,867 diabetic and 2,855 non-diabetic participants in the TCGS cohort, interestingly demonstrating that the risk of developing T2D was almost two times higher in top PRS quintile compared with the lowest quintile after adjusting for other known risk factors.Entities:
Mesh:
Substances:
Year: 2020 PMID: 32814780 PMCID: PMC7438483 DOI: 10.1038/s41598-020-70725-4
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Effect allele frequency spectrum of type 2 diabetes-associated SNPs in Iranian population.
Figure 2The comparative distribution of effect allele frequencies in Iranian population versus all five populations of 1,000 Genomes Project.
Figure 3Principal Components Analysis (PCA) based on type 2 diabetes-related SNPs.
Top four genes carrying the highest number of enriched and depleted T2D-associated SNPs in various populations.
| IR | AFR | AMR | EUR | SAS | EAS | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gene | Count | Gene | Count | Gene | Count | Gene | Count | Gene | Count | Gene | Count | |
| Enriched | 62 | 77 | 24 | 63 | 28 | 30 | ||||||
| 4 | 33 | 19 | 4 | 14 | 13 | |||||||
| 4 | 31 | 3 | 1 | 4 | 2 | |||||||
| 1 | 19 | 1 | 1 | 1 | 2 | |||||||
| Depleted | 30 | 30 | 30 | 31 | 32 | 75 | ||||||
| 18 | 18 | 30 | 26 | 19 | 30 | |||||||
| 16 | 12 | 29 | 17 | 17 | 4 | |||||||
| 3 | 2 | 3 | 3 | 3 | 4 | |||||||
Figure 4Heatmap illustrates the significantly enriched or depleted risk alleles of TCF7L2 SNPs in each population. Each row and each column represent the SNP and the population, respectively.
The association of PRS with the prevalence of type 2 diabetes.
| Quintile | Sample size | PR (95% CI) | p-value |
|---|---|---|---|
| 2 (20–40%) | 713 | 0.9 (0.76, 1.1) | 0.53 |
| 3 (40–60%) | 638 | 1.05 (0.86, 1.2) | 0.6 |
| 4 (60–80%) | 826 | 1.34 (1.1, 1.6) | 0.001 |
| 5 (> 80%) | 631 | 1.44 (1.2, 1.7) | 0.00006 |
Prevalence ratio (PR) with 95% confidence intervals (95% CI) from robust Poisson regression analysis. The model is adjusted for age, sex, and BMI. The first quintile (< 20%) containing 766 individuals were considered as reference. The whole sample size was 3,574 individuals.
The PRS effect on the risk of developing type 2 diabetes.
| Quintile | Sample size | Age, sex and BMI-adjusted model | Full model | ||
|---|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | ||
| 2 (20–40%) | 767 | 0.9 (0.6, 1.2) | 0.53 | 0.93 (0.6, 1.3) | 0.7 |
| 3 (40–60%) | 726 | 1.35 (1, 1.8) | 0.04 | 1.32 (0.96, 1.8) | 0.08 |
| 4 (60–80%) | 902 | 1.5 (1.1, 2) | 0.003 | 1.45 (1.07, 1.9) | 0.01 |
| 5 (> 80%) | 825 | 1.96 (1.4, 2.5) | 0.00001 | 1.72 (1.2, 2.3) | 0. 001 |
Hazard ratio (HR) with 95% confidence intervals (95% CI) from Cox regression analysis. The full model is adjusted for age, sex, BMI, fasting plasma glucose, 2-h plasma glucose, cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol levels. The first quintile (< 20%) containing 783 individuals were considered as reference. The whole sample size was 4,003 individuals.
Figure 5The cumulative incidence of type 2 diabetes in 4,003 genotyped individuals free of T2D at baseline. Cumulative incidence presented separately in three low, moderate and high genetically risk categories.
Baseline characteristics of the TCGS cohort (1999–2017) participants used for the present study.
| Variables | Prevalent T2D cases | Incident T2D cases | Non-progress cases to T2D |
|---|---|---|---|
| Sex (Male/Female, number) | 295/424 | 515/633 | 1,163/1692 |
| Age (mean ± SD) | 53 ± 11 | 45.5 ± 12 | 35 ± 12 |
| Body mass index (mean ± SD) | 29 ± 4.5 | 28.97 ± 4.8 | 25 ± 4.3 |
| Fasting plasma glucose (mean ± SD) | 163.57 ± 60 | 96.95 ± 11.13 | 84.7 ± 6.5 |
| 2-h plasma glucose (mean ± SD) | 269.8 ± 89.23 | 127.38 ± 32.8 | 91.9 ± 19.5 |
| Cholesterol (mean ± SD) | 227.5 ± 48 | 219.23 ± 44 | 189 ± 41 |
| High density lipoprotein cholesterol (mean ± SD) | 40.52 ± 10 | 40 ± 9.5 | 42.56 ± 10.5 |
| Low density lipoprotein cholesterol (mean ± SD) | 141.5 ± 38 | 137.4 ± 34.5 | 119 ± 33.5 |
| Triglyceride (mean ± SD) | 226 ± 111.5 | 180 ± 75 | 125 ± 65 |
| Follow-up year (median, IQR) | 14 (10–17) | ||